Yu Zhiyan, Wu Yueyue, Zhang Rui, Li Yue, Zang Shufei, Liu Jun
1Department of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Endocr Connect. 2022 Oct 12;11(11). doi: 10.1530/EC-22-0174. Print 2022 Nov 1.
This study aimed to investigate the association of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis with osteoporosis in postmenopausal women and men over 50 years of age with type 2 diabetes (T2DM).
In this study, 1243 patients with T2DM (T2DM with coexistent NAFLD, n = 760; T2DM with no NAFLD, n = 483) were analysed. Non-invasive markers, NAFLD fibrosis score (NFS) and fibrosis index based on four factors (FIB-4), were applied to evaluate NAFLD fibrosis risk.
There was no significant difference in bone mineral density (BMD) between the NAFLD group and the non-NAFLD group or between males and females after adjusting for age, BMI and gender. In postmenopausal women, there was an increased risk of osteoporosis (odds ratio (OR): 4.41, 95% CI: 1.04-18.70, P = 0.039) in the FIB-4 high risk group compared to the low risk group. Similarly, in women with high risk NFS, there was an increased risk of osteoporosis (OR: 5.98, 95% CI: 1.40-25.60, P = 0.043) compared to the low risk group. Among men over 50 years old, there was no significant difference in bone mineral density between the NAFLD group and the non-NAFLD group and no significant difference between bone mineral density and incidence of osteopenia or osteoporosis among those with different NAFLD fibrosis risk.
There was a significant association of high risk for NAFLD liver fibrosis with osteoporosis in postmenopausal diabetic women but not men. In clinical practice, gender-specific evaluation of osteoporosis is needed in patients with T2DM and coexistent NAFLD.
本研究旨在调查50岁以上2型糖尿病(T2DM)绝经后女性和男性中非酒精性脂肪性肝病(NAFLD)及肝纤维化与骨质疏松症之间的关联。
本研究分析了1243例T2DM患者(合并NAFLD的T2DM患者,n = 760;无NAFLD的T2DM患者,n = 483)。应用非侵入性标志物,即NAFLD纤维化评分(NFS)和基于四项因素的纤维化指数(FIB-4)来评估NAFLD纤维化风险。
在校正年龄、体重指数和性别后,NAFLD组与非NAFLD组之间或男性与女性之间的骨密度(BMD)无显著差异。在绝经后女性中,与低风险组相比,FIB-4高风险组骨质疏松症风险增加(比值比(OR):4.41,95%置信区间:1.04 - 18.70,P = 0.039)。同样,与低风险组相比,NFS高风险的女性骨质疏松症风险增加(OR:5.98,95%置信区间:1.40 - 25.60,P = 0.043)。在50岁以上男性中,NAFLD组与非NAFLD组之间的骨密度无显著差异,且不同NAFLD纤维化风险者之间的骨密度与骨质减少或骨质疏松症发病率无显著差异。
绝经后糖尿病女性中NAFLD肝纤维化高风险与骨质疏松症存在显著关联,而男性中不存在。在临床实践中,对于合并NAFLD的T2DM患者,需要进行针对性别的骨质疏松症评估。